Prostate International最新文献

{"title":"Incidence and risk factors for dermatologic adverse events following apalutamide use: a real-world data analysis in the Korean population","authors":"Sangmin Lee,&nbsp;Bumjin Lim,&nbsp;Jung Kwon Kim,&nbsp;In Gab Jeong,&nbsp;Jun Hyuk Hong,&nbsp;Hanjong Ahn,&nbsp;Jungyo Suh","doi":"10.1016/j.prnil.2024.10.002","DOIUrl":"10.1016/j.prnil.2024.10.002","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to assess the incidence, severity, and onset of dermatologic adverse events (dAEs) in Korean patients treated with apalutamide for metastatic hormone-sensitive prostate cancer (mHSPC) and to identify clinical and laboratory predisposing factors.</div></div><div><h3>Materials and methods</h3><div>We retrospectively analyzed data of patients treated with apalutamide for mHSPC at a tertiary referral center in Korea between April 2023 and March 2024. Patients with a radical prostatectomy history or insufficient data were excluded. The onset, severity, and management of dAEs were evaluated and compared between patients with and without dAEs. Clinical and laboratory data from 1 month prior to apalutamide administration were collected. Logistic regression was performed to identify predictors of dAEs, and the predictive value of serum albumin levels was analyzed using the receiver operating characteristic (ROC) curve.</div></div><div><h3>Results</h3><div>Twenty-six (40.0%) of the 65 patients developed dAEs, including nine (13.8%) with Grade ≥3 events. The median onset of dAEs was 66.5 (45–78) days. Patients with dAEs had significantly lower initial prostate-specific antigen levels (70.4 vs. 301.6 ng/mL), higher Eastern Cooperative Oncology Group Performance Status (ECOG-PS; 30.8% vs. 5.1%), and lower serum albumin levels (3.8 vs. 4.1 g/dL). Logistic regression identified elevated Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) and hypoalbuminemia as significant predictors of dAEs. ROC analysis for serum albumin levels produced an area under the curve of 0.739, with a cutoff value of 3.85 g/dL, yielding a sensitivity and specificity of 65.4% and 74.4%, respectively.</div></div><div><h3>Conclusion</h3><div>dAEs are prevalent in Korean patients treated with apalutamide for mHSPC, with ECOG-PS and serum albumin levels identified as significant risk factors.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 1","pages":"Pages 10-14"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study","authors":"Fumihiko Urabe ,&nbsp;Hirokazu Kagawa ,&nbsp;Takafumi Yanagisawa ,&nbsp;Hidetsugu Takahashi ,&nbsp;Masaki Hashimoto ,&nbsp;Shuhei Hara ,&nbsp;Wataru Fukuokaya ,&nbsp;Yu Imai ,&nbsp;Kosuke Iwatani ,&nbsp;Taro Igarashi ,&nbsp;Mahito Atsuta ,&nbsp;Kojiro Tashiro ,&nbsp;Masaya Murakami ,&nbsp;Shunsuke Tsuzuki ,&nbsp;Brendan A. Yanada ,&nbsp;Toshihiro Yamamoto ,&nbsp;Kenichi Hata ,&nbsp;Hiroki Yamada ,&nbsp;Jun Miki ,&nbsp;Takahiro Kimura","doi":"10.1016/j.prnil.2024.11.003","DOIUrl":"10.1016/j.prnil.2024.11.003","url":null,"abstract":"<div><h3>Background</h3><div>To compare adverse event (AE) profiles between patients with prostate cancer receiving triplet therapy (docetaxel, androgen receptor signaling inhibitors [ARSIs], and androgen deprivation therapy [ADT]) and those receiving docetaxel-based therapy (docetaxel and ADT). Additionally, we sought to identify risk factors for severe AEs associated with these treatment regimens.</div></div><div><h3>Materials and methods</h3><div>In this retrospective, multicenter study, we included 359 patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) or metastatic castration-resistant prostate cancer (mCRPC) who were treated with docetaxel. We analyzed patient demographics, hematologic and non-hematologic AEs, and risk factors for severe AEs. Logistic regression models were used to assess risk factors.</div></div><div><h3>Results</h3><div>There were no significant differences in the incidence of ≥ grade 3 neutropenia or febrile neutropenia (FN) between the triplet and docetaxel-based therapy groups when stratified by the use of primary prophylaxis. Non-hematologic AEs, especially fatigue, were more frequent in the mCRPC group compared to the triplet therapy group. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) significantly reduced the risk of severe neutropenia (odds ratio [OR] 0.092, <em>P</em> &lt; 0.001) and FN (OR 0.13, <em>P</em> = 0.007).</div></div><div><h3>Conclusion</h3><div>This study represents the first real-world analysis comparing the adverse event profiles of triplet therapy and docetaxel-based therapy in Japanese patients with mCSPC, as well as docetaxel-based therapy in those with mCRPC. No significant difference in severe AEs was observed between the therapies. Primary prophylaxis with G-CSF proved critical in reducing severe neutropenia and FN, underscoring its importance in enhancing the safety and efficacy of docetaxel-based therapies.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 1","pages":"Pages 41-48"},"PeriodicalIF":2.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparisons of three scoring systems based on biparametric magnetic resonance imaging for prediction of clinically significant prostate cancer","authors":"Wei Li ,&nbsp;Haibing Xu ,&nbsp;Wenwen Shang,&nbsp;Guohui Hong","doi":"10.1016/j.prnil.2024.08.002","DOIUrl":"10.1016/j.prnil.2024.08.002","url":null,"abstract":"<div><h3>Purpose</h3><div>In this study, we aimed to validate and compare three scoring systems based on biparametric magnetic resonance imaging (bpMRI) for the detection of clinically significant prostate cancer (csPCa) in biopsy-naïve patients.</div></div><div><h3>Method</h3><div>In this study, we included patients who underwent MRI examinations between January 2018 and December 2022, with MRI-targeted fusion biopsy (MRGB) as the reference standard. The MRI findings were categorized using three bpMRI-based scorings, in all of them the diffusion-weighted imaging (DWI) was the dominant sequence for peripheral zone (PZ) and T2-weighed imaging (T2WI) was the dominant sequence for transition zone (TZ). We also used the Prostate Imaging Reporting and Data System version (PI-RADS) v2.1 to evaluate each lesion. For each scoring, we calculated the sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and area under the receiver operating characteristic (ROC) curves (AUC).</div></div><div><h3>Results</h3><div>The calculated AUC for three bpMRI-based scorings were 83.2% (95% CI 78.8%–87.6%), 85.0% (95% CI 80.8%–89.3%), 82.9% (95% CI 78.4%–87.5%), and 86.0% (95% CI 81.8%–90.1%), respectively. Scoring 2 exhibited significantly superior performance than scoring 1 (<em>P</em> = 0.01) and scoring 3 (<em>P</em> &lt; 0.001). Moreover, the accuracy of scoring 2 was not decreased significantly as compared to PI-RADS v2.1 (<em>P</em> = 0.05). There was no significant difference between 3 bpMRI-based scorings and with PI-RADS in TZ. However, although scoring 2 yielded the highest AUC, it was still notably inferior to PI-RADS (<em>P</em> = 0.02).</div></div><div><h3>Conclusion</h3><div>All three bpMRI-based scorings demonstrated favorite diagnostic accuracy, and scoring 2 performed significantly better than the other two bpMRI-based scorings. Notably, scoring 2 was not significantly inferior to the full-sequence PI-RADS v2.1 in terms of sensitivity and specificity.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 4","pages":"Pages 201-206"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole gland versus partial gland ablation in patients with localized prostate cancer treated by high-intensity focused ultrasound ablation","authors":"Hae Sung Lee ,&nbsp;Sang Hun Song ,&nbsp;Hakmin Lee ,&nbsp;Sung Kyu Hong","doi":"10.1016/j.prnil.2024.09.001","DOIUrl":"10.1016/j.prnil.2024.09.001","url":null,"abstract":"<div><h3>Background</h3><div>Focal therapy is considered one of the treatment options for localized prostate cancer (PCa), particularly for low or very-low-risk patients. In this study, we compared the mid-term oncological outcomes in localized PCa patients treated with high-intensity focused ultrasound (HIFU).</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 237 patients who underwent HIFU for localized PCa. Patients were divided into two groups based on ablation type: whole gland ablation (WGA) and partial gland ablation (PGA). Follow-up biopsies were performed after one year postoperatively, and the oncological outcomes were compared between the groups.</div></div><div><h3>Results</h3><div>Among the total of 237 patients, 54 subjects were treated by WGA and 183 subjects by PGA. After one year postoperatively, follow-up biopsies were conducted on 199 patients, revealing residual cancer in 21.4% of WGA group and 15.3% of PGA group. Additionally, clinically significant (CS) cancer was observed in 14.3% of WGA group and 8.3% of PGA group. Survival analyses revealed significantly longer failure-free (<em>P</em> &lt; 0.001) and salvage-free survival (<em>P</em> &lt; 0.001) in WGA group than in PGA group. Similarly, in the intermediate—high risk group, WGA group exhibited longer failure-free (<em>P</em> = 0.005) and salvage-free survival (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>HIFU was performed with acceptable oncological outcomes in localized PCa. Despite higher proportion of high-risk patients in WGA group, WGA was associated with significantly better failure-free survival and salvage-free survival. Further prospective and multi-center studies are warranted.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 4","pages":"Pages 213-218"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the efficacy of tadalafil and tamsulosin for managing erectile dysfunction and lower urinary tract symptoms in prostate brachytherapy patients: a prospective study","authors":"Nozomi Hayakawa ,&nbsp;Ryuichi Mizuno ,&nbsp;Tomoki Tanaka ,&nbsp;Yutaka Shiraishi ,&nbsp;Kazuhiro Matsumoto ,&nbsp;Takeo Kosaka ,&nbsp;Eiji Kikuchi ,&nbsp;Mototsugu Oya","doi":"10.1016/j.prnil.2024.09.004","DOIUrl":"10.1016/j.prnil.2024.09.004","url":null,"abstract":"<div><h3>Introduction</h3><div>Adverse events, such as erectile dysfunction (ED) and lower urinary tract symptoms (LUTS), are significant concerns in prostate cancer (PCa) patients treated with Iodine 125 (I-125) low-dose rate (LDR) prostate brachytherapy (PB). Alpha antagonists and phosphodiesterase-5 inhibitors are used to manage these events. The present study compared the efficacy of low-dose tadalafil with that of tamsulosin for concomitant ED and LUTS in PCa patients treated with I-125 LDR PB.</div></div><div><h3>Materials and methods</h3><div>One hundred and seventeen patients who received PB for low- or intermediate-risk localized PCa were analyzed. They were randomized into two groups, one receiving tamsulosin (<em>N</em> = 58) and the other receiving low-dose tadalafil (<em>N</em> = 59) immediately after PB. Sexual and urinary functions were assessed at various time points post-PB using questionnaires and objective measurements. The primary endpoint was sexual function measured by the International Index of Erectile Function-15 (IIEF-15) EF domain scores 6 months after PB. Secondary endpoints were sexual function measured by total IIEF-15 scores and Erection Hardness Scores 6 months after PB. The exploratory endpoint was the LUTS status 6 months after PB.</div></div><div><h3>Results</h3><div>No significant differences were observed in baseline characteristics between the two groups. Tadalafil exerted stronger effects on sexual function, particularly erection hardness, than tamsulosin. No significant differences were observed in the management of LUTS between both treatments.</div></div><div><h3>Conclusion</h3><div>Low-dose tadalafil and tamsulosin may manage LUTS equally after PB. Low-dose tadalafil may contribute to the maintenance of erectile function, particularly erection hardness, after PB; therefore, it is a viable option for patients with baseline erectile function.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 4","pages":"Pages 231-237"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of extracorporeal shockwave therapy on chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled study","authors":"Kyung Jae Hur ,&nbsp;Woong Jin Bae ,&nbsp;U-Syn Ha ,&nbsp;Soomin Kim ,&nbsp;JunJie Piao ,&nbsp;Kyung-Hwa Jeon ,&nbsp;Cheong Woon Cheon ,&nbsp;Dae Up Kang ,&nbsp;Jong Woong Lee ,&nbsp;Dongho Shin ,&nbsp;Sae Woong Kim","doi":"10.1016/j.prnil.2024.06.003","DOIUrl":"10.1016/j.prnil.2024.06.003","url":null,"abstract":"<div><h3>Purpose</h3><div>This study aimed to investigate the efficacy and safety of extracorporeal shock wave therapy (ESWT) over an 8-week period in individuals diagnosed with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) compared to a control group.</div></div><div><h3>Materials and methods</h3><div>This prospective, double-blind, placebo-controlled study enrolled 46 participants diagnosed with CP/CPPS, who were randomly assigned to either the treatment group or the control group in a 2:1 ratio. In the treatment group, ESWT was administered at the perineum once a week for 8 weeks. CP/CPPS-related symptoms were assessed using the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH–CPSI). Pain and erectile function were measured using the Visual Analogue Scale (VAS) and the International Index of Erectile Function-Erectile Function (IIEF-EF).</div></div><div><h3>Results</h3><div>The primary efficacy assessment variable, the change in NIH–CPSI total score at 4 weeks after the end of the 8-week treatment compared to baseline, was significantly improved (<em>P</em> = 0.0225) in the treatment group (−11.27 ± 8.39) compared to the control group (−5.44 ± 5.73). Regarding the secondary efficacy assessment variables, the treatment group showed significant decreases compared to the control group in change in NIH–CPSI total score (<em>P</em> = 0.0055) at the end of the 8-week treatment compared to baseline, along with significant decreases in pain and quality of life scores, as well as VAS assessments at the end of the 8-week treatment and 4 weeks after the end of treatment (<em>P</em> &lt; 0.05). Moreover, in the evaluation conducted to assess improvement in sexual function, the treatment group showed a significant increase compared to baseline than the control group in the IIEF total score at 4 weeks after the end of the treatment (<em>P</em> = 0.0364). No patients experienced severe side effects related to ESWT during the therapeutic period or the follow-up duration.</div></div><div><h3>Conclusions</h3><div>The efficacy assessment in this clinical trial indicates that extracorporeal shock wave therapy is expected to have a symptomic improvement effect on CP/CPPS.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 4","pages":"Pages 195-200"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141407358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risks of Asian patients on androgen-receptor-targeted agents for prostate cancer: a systematic review and meta-analysis","authors":"Lin Kyaw ,&nbsp;Qi Y. Lim ,&nbsp;Yu X.T. Law ,&nbsp;Chloe S.H. Ong ,&nbsp;Wei T. Loke ,&nbsp;Edmund Chiong ,&nbsp;Ho Y. Tiong","doi":"10.1016/j.prnil.2024.07.004","DOIUrl":"10.1016/j.prnil.2024.07.004","url":null,"abstract":"<div><h3>Background</h3><div>Prostate cancer is now one of the most prevalent cancers in men in Asia. As the average life expectancy of Asian males with prostate cancer increases with the availability of treatment options, the possible risk of cardiac-related adverse effects arising from androgen-receptor-targeted agents (ARTAs) may be increased due to the greater exposure. We aim to perform a meta-analysis on the incidence of cardiac-related adverse events in Asian patients with prostate cancer treated with ARTAs.</div></div><div><h3>Materials and methods</h3><div>Databases were thoroughly searched for relevant articles. The Patient Intervention Comparison Outcome Study type model was used to frame our clinical question, and 2 independent authors went through several rounds of screening to select the final included studies. A meta-analysis was conducted using the Cochran–Mantel–Haenszel method. Quality assessment was carried out with the Cochrane risk-of-bias tool RoB 2.</div></div><div><h3>Results</h3><div>Seven randomized controlled trials were included for the final meta-analysis. Use of ARTA in Asian men did not show any significant increase in the total number of cardiac-related adverse events (risk ratio [RR]: 1.66 [0.84–3.26], p = 0.14). However, there was increase in incidence of hypertension (RR: 2.30 [1.41–3.73], p = 0.0008) and hypertension crises (RR: 16.87 [2.13–133.34], p = 0.007). A subgroup analysis of the type of ARTA used showed enzalutamide having the highest risk of hypertension (RR: 5.86 [2.10–16.38], p = 0.0008).</div></div><div><h3>Conclusion</h3><div>:Although ARTAs did not show any significant increase in incidence of cardiac-related adverse events, there is an increased risk of hypertension especially with the use of enzalutamide. With this knowledge, closer blood pressure monitoring is needed for patients started on ARTA, especially enzalutamide.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 4","pages":"Pages 186-194"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between behavioral habits and physical health status in prostate cancer patients: a large US national health-related survey","authors":"Chang-Rong Chen ,&nbsp;Logan Briggs ,&nbsp;Mara Koelker ,&nbsp;Benjamin V. Stone ,&nbsp;Khalid Alkhatib ,&nbsp;Muhieddine Labban ,&nbsp;Alberto Briganti ,&nbsp;Francesco Montorsi ,&nbsp;Giorgio Gandaglia ,&nbsp;Quoc-Dien Trinh","doi":"10.1016/j.prnil.2024.08.001","DOIUrl":"10.1016/j.prnil.2024.08.001","url":null,"abstract":"<div><h3>Background</h3><div>The impact of behavioral habits such as exercise on the physical health of prostate cancer (PCa) patients is poorly understood. We aimed to investigate PCa patients' exercise habits and the association between exercise and self-reported physical health status.</div></div><div><h3>Methods</h3><div>The 2016–2020 Behavioral Risk Factor Surveillance System (BRFSS) databases were used to identify men with a history of PCa. We identified patients with self-reported PCa diagnosis and excluded the non-male gender respondents in the self-reported PCa patients. We performed descriptive statistics and multivariable logistic regression analysis examining the association between exercise and poor physical health status. Our exposure of interest was the amount of physical exercise, and primary outcome was poor physical health status, defined as &gt;14 self-reported days per month when patients felt “physical health is not good.” Covariates included age, body mass index (BMI), income, treatment, smoking, and exercise frequency.</div></div><div><h3>Results</h3><div>From 2,193,981 weighted survey participants, we identified 3,952 men with a history of PCa. Of these, 75% of participants reported exercise within the last month. In adjusted analyses among men with a history of PCa, exercise (OR 0.50, 95% CI 0.40–0.64, <em>P</em> &lt; 0.001) was associated with lower odds of poor physical health status. Other independent predictors of poor physical health included income (High: OR 0.27, 95% CI 0.18–0.41, <em>P</em> &lt; 0.01), BMI (underweight: OR 3.78, 95% CI 1.38–10.37, <em>P</em> = 0.01), treatment status (Active: OR 1.76, 95% CI 1.05–2.94, <em>P</em> = 0.03), smoking status (Active: OR 1.64, 95% CI 1.13–2.38, <em>P</em> = 0.01).</div></div><div><h3>Conclusion</h3><div>Our BRFSS cross-sectional study concluded that exercise among men with a history of PCa, even once per month, is associated with decreased odds of self-reported poor physical health; therefore, exercise programs should be considered for sedentary PCa patients.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 4","pages":"Pages 207-212"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142189065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weekly versus 2-weekly versus 3-weekly docetaxel to treat metastatic castration-resistant prostate cancer","authors":"Hyeong Dong Yuk ,&nbsp;Miso Kim ,&nbsp;Bhumsuk Keam ,&nbsp;Ja Hyeon Ku ,&nbsp;Cheol Kwak ,&nbsp;Chang Wook Jeong","doi":"10.1016/j.prnil.2024.09.002","DOIUrl":"10.1016/j.prnil.2024.09.002","url":null,"abstract":"<div><h3>Background</h3><div>To compare the efficacy and toxicity of docetaxel treatment regimens in metastatic castration-resistant prostate cancer (mCRPC).</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 162 patients diagnosed with mCRPC who underwent docetaxel chemotherapy between 2009 and 2020. The patients were divided into three groups according to the dosage and interval of docetaxel (DCT) chemotherapy regimen: 30 mL/m² weekly, 50 mL/m² biweekly (every 2 weeks), and 75 mL/m² triweekly (every 3 weeks).</div></div><div><h3>Results</h3><div>There were no significant differences in the prostate-specific antigen (PSA) response rates (<em>P</em> = 0.709). The median time to progression was 3.0 [interquartile range (IQR 2.0–5.3)] months, 5.0 (IQR 2.0–13.0) months, and 5.0 (IQR 3.0–12.0) months in the weekly, biweekly, and triweekly groups, respectively (<em>P</em> = 0.062). The median overall survival (OS) was 12.5 (IQR 6.0–14.0) months, 18.8 (IQR 5.5–23.5) months, and 22.9 (IQR 11.0–33.0) months in the weekly, biweekly, and triweekly groups, respectively (<em>P</em> &lt; 0.001). There were no differences in all toxicity and Grade 3 or higher toxicity. In Cox multivariate regression analysis, the Eastern Cooperative Oncology Group performance status (ECOG-PS), response to chemotherapy, and chemotherapy cycle also affected the PFS. Age, ECOG-PS, and chemotherapy cycle affected the OS.</div></div><div><h3>Conclusions</h3><div>The various options for optimal chemotherapy are indicated depending on the patient’s conditions during the diagnosis of mCRPC. Treatment with DCT at 2-week or even 1-week intervals appears to be well tolerated in men diagnosed with mCRPC and represents a useful option when the conventional triweekly regimen is not tolerated due to poor patient condition.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 4","pages":"Pages 219-223"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of bladder neck sparing on continence outcomes of robotic-assisted radical prostatectomy: a systemic review and metaanalysis","authors":"Joongwon Choi ,&nbsp;Yun-Jung Yang ,&nbsp;Chung Un Lee ,&nbsp;Jung Hoon Kim ,&nbsp;Jin Wook Kim ,&nbsp;Jong Hyun Tae ,&nbsp;Se Young Choi ,&nbsp;In Ho Chang ,&nbsp;Eun-Jung Yang ,&nbsp;Yong Seong Lee","doi":"10.1016/j.prnil.2024.04.004","DOIUrl":"10.1016/j.prnil.2024.04.004","url":null,"abstract":"<div><div>Restoration of postoperative urinary continence after robot-assisted radical prostatectomy (RARP) is affected by diverse factors. We compared the pad-free and positive margin rates of patients who underwent RARP with or without bladder neck sparing (BNS) for prostate cancer. During this systematic review and metaanalysis, we performed an electronic search of the Web of Science, Embase, Cochrane Central Register of Controlled Trials, and PubMed to find original articles comparing RARP with and without BNS for prostate cancer. We identified six studies (2,351 patients in total) who underwent RARP with or without BNS. A metaanalysis of the pad-free rate at 3 months was performed. The overall pad-free rate at 3 months for patients who underwent RARP with BNS was significantly higher than that of patients who underwent RARP alone (control group) (odds ratio, 1.86; 95% confidence interval [CI], 1.22–2.82), with high heterogeneity (<em>P</em> = 0.005; I² = 67.45%). The pad-free rates at 7 days, 6 months, and 1 year and positive surgical margin rates of patients who underwent BNS were not significantly different than those in the control group. Although no statistical difference was observed, the catheterization period of the BNS group was shorter than that of the control group (standardized mean difference = −0.08; 95% CI, −0.16 to 0.01). Although RARP with BNS did not affect the long-term outcome of continence, it had a significant effect on the early recovery of continence.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"12 4","pages":"Pages 179-185"},"PeriodicalIF":2.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141063324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}